Katia Cagossi

2.1k total citations
42 papers, 612 citations indexed

About

Katia Cagossi is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Katia Cagossi has authored 42 papers receiving a total of 612 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 19 papers in Cancer Research and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Katia Cagossi's work include Breast Cancer Treatment Studies (18 papers), HER2/EGFR in Cancer Research (17 papers) and Advanced Breast Cancer Therapies (14 papers). Katia Cagossi is often cited by papers focused on Breast Cancer Treatment Studies (18 papers), HER2/EGFR in Cancer Research (17 papers) and Advanced Breast Cancer Therapies (14 papers). Katia Cagossi collaborates with scholars based in Italy, Spain and United States. Katia Cagossi's co-authors include Mario Luppi, Giuseppe Torelli, Monica Morselli, Leonardo Ferrara, Giovanni Emilia, Giuseppe Longo, Sergio Amarri, Giancarlo Bisagni, Pierfranco Conté and Valentina Guarneri and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Katia Cagossi

39 papers receiving 598 citations

Peers

Countries citing papers authored by Katia Cagossi

Since Specialization

Citations

This map shows the geographic impact of Katia Cagossi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katia Cagossi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katia Cagossi more than expected).

Fields of papers citing papers by Katia Cagossi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katia Cagossi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katia Cagossi. The network helps show where Katia Cagossi may publish in the future.

Co-authorship network of co-authors of Katia Cagossi

This figure shows the co-authorship network connecting the top 25 collaborators of Katia Cagossi. A scholar is included among the top collaborators of Katia Cagossi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katia Cagossi. Katia Cagossi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications 2025 ·npj Breast Cancer ·(unknown), Michele Bottosso, (unknown), Federica Miglietta, Daniele Generali, Antonino Musolino, (unknown), Grazia Maria Vernaci, Tommaso Giarratano, Rocco Cappellesso, Silvio Bicciato, Federico Piacentini, Enrico Tagliafico, Katia Cagossi, Anna Tosi, Francesca Schiavi, (unknown), (unknown), Valentina Guarneri	0
2	Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase 3 trial in noninvasive breast cancer 2025 ·JNCI Journal of the National Cancer Institute ·Alessio Carbone, Martino Oliva, Matteo Puntoni, Aliana Guerrieri‐Gonzaga, (unknown), Matteo Lazzeroni, Davide Serrano, Livia Giordano, Maria Digennaro, Laura Cortesi, (unknown), Katia Cagossi, (unknown), Patrizia Serra, (unknown), Bernardo Bonanni, Andrea DeCensi	0
3	350P Long-term gynaecological safety and benign breast disease on low-dose tamoxifen: 10-year results from the TAM-01 phase III trial 2025 ·Annals of Oncology ·Annalucia Carbone, (unknown), Matteo Puntoni, (unknown), (unknown), (unknown), (unknown), Leone Giordano, Maria Digennaro, (unknown), (unknown), Katia Cagossi, Giuseppe Aprile, Fabio Falcini, Elisa Gallerani, (unknown), (unknown)	1
4	Association of tumor-infiltrating lymphocytes (TILs) and immune signatures with PAM50 intrinsic subtyping hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of two multicentric neoadjuvant trials. 2024 ·Journal of Clinical Oncology ·Gaia Griguolo, Laia Paré, Federica Miglietta, Michele Bottosso, Daniele Generali, Antonio Frassoldati, Antonino Musolino, Simon Spazzapan, Grazia Maria Vernaci, Tommaso Giarratano, Rocco Cappellesso, Giancarlo Bisagni, Federico Piacentini, Enrico Tagliafico, Katia Cagossi, Claudia Pinato, Francesca Schiavi, Aleix Prat, Maria Vittoria Dieci, Valentina Guarneri	0
5	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 2021 ·European Journal of Cancer ·Valentina Guarneri, Maria Vittoria Dieci, Gaia Griguolo, Federica Miglietta, Fabio Girardi, Giancarlo Bisagni, Daniele Generali, Katia Cagossi, Samanta Sarti, Antonio Frassoldati, Lorenzo Gianni, Luigi Cavanna, Graziella Pinotti, Antonino Musolino, Federico Piacentini, Saverio Cinieri, Aleix Prat, Pierfranco Conté	26
6	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer 2021 ·npj Breast Cancer ·Gaia Griguolo, Maria Vittoria Dieci, Laia Paré, Federica Miglietta, Daniele Generali, Antonio Frassoldati, Luigi Cavanna, Giancarlo Bisagni, Federico Piacentini, Enrico Tagliafico, Katia Cagossi, Guido Ficarra, Aleix Prat, Pierfranco Conté, Valentina Guarneri	15
7	19P PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study 2020 ·Annals of Oncology ·Valentina Guarneri, Maria Vittoria Dieci, Giancarlo Bisagni, Alba A. Brandes, Antonio Frassoldati, Luigi Cavanna, Antonino Musolino, Francesco Giotta, Anita Rimanti, Ornella Garrone, (unknown), Katia Cagossi, Oriana Nanni, Federico Piacentini, Enrico Orvieto, Matteo Curtarello, Núria Chic, Roberto D’Amico, Aleix Prat, Pierfranco Conté	3
8	Scalp Cooling in Daily Clinical Practice for Breast Cancer Patients Undergoing Curative Chemotherapy: A Multicenter Interventional Study 2019 ·Asia-Pacific Journal of Oncology Nursing ·(unknown), Giorgia Razzini, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Katia Cagossi, (unknown), Fabrizio Artioli	14
9	Abstract GS3-01: A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ 2019 ·Cancer Research ·Andrea DeCensi, Matteo Puntoni, (unknown), Franca Avino, Laura Cortesi, Michela Donadio, (unknown), Fabio Falcini, Marcella Gulisano, Maria Digennaro, A. Tienghi, Katia Cagossi, G. Pinotti, (unknown), (unknown), Luca Boni, Bernardo Bonanni	5
10	Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study 2018 ·European Journal of Cancer ·Milvia Zambetti, Filippo Montemurro, Paolo Morandi, Claudio Zamagni, Alba A. Brandes, Giancarlo Bisagni, Katia Cagossi, Carmelo Bengala, Stefania Gori, Claudio Iannacone, (unknown), Luca Gianni	9
11	Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials 2017 ·Breast Cancer Research and Treatment ·Maria Vittoria Dieci, Antonio Frassoldati, Daniele Generali, Giancarlo Bisagni, Federico Piacentini, Luigi Cavanna, Katia Cagossi, Fabio Puglisi, Andrea Michelotti, Rossana Berardi, Giuseppe Luigi Banna, Aïcha Goubar, Guido Ficarra, Gaia Griguolo, Pierfranco Conté, Valentina Guarneri	20
12	Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 2016 ·The Pharmacogenomics Journal ·Antonino Musolino, Nadia Naldi, Maria Vittoria Dieci, (unknown), Anita Rimanti, Daniela Boggiani, Paolo Sgargi, Daniele Generali, Federico Piacentini, (unknown), Katia Cagossi, Lorenzo Gianni, Samanta Sarti, Giancarlo Bisagni, Andrea Ardizzoni, Pierfranco Conté, Valentina Guarneri	20
13	Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer 2015 ·The Oncologist ·Valentina Guarneri, Maria Vittoria Dieci, Antonio Frassoldati, Antonino Maiorana, Guido Ficarra, Stefania Bettelli, Enrico Tagliafico, Silvio Bicciato, Daniele Generali, Katia Cagossi, Giancarlo Bisagni, Samanta Sarti, Antonino Musolino, Catherine Ellis, Rocco J. Crescenzo, Pierfranco Conté	67
14	Abstract PD1-1: Tumor infiltrating lymphocytes and correlation with outcome in the Cher-LOB study 2015 ·Cancer Research ·Maria Vittoria Dieci, Giancarlo Bisagni, Katia Cagossi, Alberto Bottini, Samanta Sarti, Federico Piacentini, Pierfranco Conté, Valentina Guarneri	6
15	A Late Complication of Fat Autografting in Breast Augmentation 2009 ·Plastic & Reconstructive Surgery ·Maria Grazia Lazzaretti, (unknown), (unknown), Katia Cagossi, Fabrizio Artioli	7
16	Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005 2009 ·Journal of Experimental & Clinical Cancer Research ·Prisco Piscitelli, Antonio Santoriello, Luigi Buonaguro, Massimo Di Maïo, Giovanni Iolascon, Francesca Gimigliano, Alessandra Marinelli, A. Distante, (unknown), (unknown), Katia Cagossi, Fabrizio Artioli, Michele Santangelo, Alfredo Fucito, Raffaele Gimigliano, Maria Luisa Brandi, M. Crespi, Antonio Giordano	20
17	CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY 2007 ·IRIS UNIMORE (University of Modena and Reggio Emilia) ·Valentina Guarneri, Antonio Frassoldati, Katia Cagossi, Alberto Bottini, Luigi Cavanna, Andrea Michelotti, Gordana Jovic, Federico Piacentini, Cristina Oliva, Pierfranco Conté	1
18	Immunoglobulin Mutational Status Detected through Single-Round Amplification of Partial VH Region Represents a Good Prognostic Marker for Clinical Outcome in Chronic Lymphocytic Leukemia 2005 ·Journal of Molecular Diagnostics ·Roberto Marasca, Rossana Maffei, Monica Morselli, Patrizia Zucchini, Ilaria Castelli, Silvia Martinelli, (unknown), (unknown), (unknown), Giovanna Leonardi, Katia Cagossi, (unknown), Giuseppe Torelli	8
19	Expression of Cell-Homologous Genes of Human Herpesvirus-8 in Human Immunodeficiency Virus-Negative Lymphoproliferative Diseases 1999 ·Blood ·Mario Luppi, Patrizia Barozzi, Antonino Maiorana, Raffaella Trovato, Roberto Marasca, Monica Morselli, Katia Cagossi, Giuseppe Torelli	14
20	The oncogenic 30 and 69 bp deletion variants of the EBV LMP-1 gene are common in HIV-negative lymphoproliferations, both malignant and benign 1999 ·Annals of Oncology ·Patrizia Barozzi, Mario Luppi, Katia Cagossi, Antonino Maiorana, Roberto Marasca, T Artusi, Simonetta Poggi, Stefano Pileri, (unknown)	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact